The promise of synthetic biology is on full display. Breaking news at BIO 2017, Synthetic Genomics, Inc. and ExxonMobil will discuss scientific breakthroughs – soon to be published in a major peer reviewed journal – for developing a “fat and fit” algae strain with high oil production and rapid growth for the production of a renewable, low-emission alternative to legacy fossil fuel. This program represents a key area of research in ExxonMobil’s broader advanced biofuels and sustainable energy research portfolio. This innovation adds to a series of advances in the past year for Synthetic Genomics as they have accelerated key programs, including engineered cells to replace E. coli and CHO in biologics production, automated production of DNA constructs for human clinical trials on the BioXp™ 3200 System, and pharma partnerships employing their proprietary RNA platform for novel therapeutics.
Session ID: 26749